Details of the Drug

General Information of Drug (ID: DMK34MZ)

Drug Name
Xilonix
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [1]
Influenza virus infection 1E30-1E32 Phase 3 [2]
Non-small-cell lung cancer 2C25.Y Phase 2 [3]
Cross-matching ID
TTD ID
D0YO4C
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-1 alpha (IL1A) TTPM6HI IL1A_HUMAN Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Colorectal cancer
ICD Disease Classification 2B91.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-1 alpha (IL1A) DTT IL1A 7.52E-01 1.41E-02 0.09
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02138422) A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Xbiotech.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of xbiotech.